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chronic injury stimulus resulting in inflammatory leukocyte
recruitment and microcirculatory activation. Once leuko-
cytes enter the dermal interstitium, a series of ill-defined
pathologic, cellular events occur. These events may include
activation of matrix metalloproteinases (MMPs) and/or
their tissue inhibitors (TIMPs). These proteases are likely
candidates for CVI-induced lower-extremity dermal alter-
ations because of their involvement in tissue remodeling
and their association with transforming growth factor–β1
(TGF-β1).4,5 MMPs are a tightly regulated group of pro-
teases that play an important role in tissue remodeling and
extracellular matrix (ECM) degradation. Because MMPs
are structurally related and contain an active zinc and cal-
cium stabilizing binding site, each MMP can degrade a
wide range of ECM proteins with differences in efficiency.6
TGF-β1 is a cytokine normally associated with tissue
remodeling and regulation of MMP activity. However, the
scientific literature contains very few systematic studies
relating either TGF-β1 or MMPs to CVI disease severity.
Under pathologic circumstances requiring wound
healing, excessive amounts of TGF-β1 may cause tissue
fibroplasia by increasing ECM synthesis, inhibiting
Chronic venous insufficiency (CVI) is observed as a
consequence of lower-extremity venous valvular reflux.
The venous hypertension that subsequently develops is
transmitted to the dermal microcirculation, resulting in the
extravasation of red blood cells and macromolecules, like
fibrinogen and α2-macroglobulin, into the dermal intersti-
tium.1-3 Presumably, these cells and molecules represent a
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Purpose: Increased transforming growth factor–β1 (TGF-β1) activity is associated with chronic venous insufficiency
(CVI) disease progression and dermal skin pathology. Because TGF-β1 stimulates collagen synthesis and alters the lev-
els of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), we investigated the hypothesis that increased
TGF-β1 activity is associated with differences in messenger RNA and protein levels of MMPs and TIMP-1 in patients
with CVI.
Methods: One hundred ten biopsies of the lower calf and lower thigh in 73 patients were snap frozen in liquid nitrogen
and stratified into six groups according to the clinical etiologic anatomic distribution pathophysiology disease classifi-
cation. One set of lower-calf and lower-thigh biopsies were analyzed for MMP-1 and TIMP-1 gene expression with
quantitative reverse transcription and competitive polymerase chain reaction. A second set of biopsies was analyzed for
the active and latent forms of MMP-1, MMP-2, and MMP-9 as well as for TIMP-1 by western blotting, gelatin zymog-
raphy, and tissue localization by immunohistochemistry (IHC).
Results: Compared with the control, MMP-1 messenger RNA was increased in class-4 and class-6 patients (P ≤ .01),
whereas TIMP-1 was increased in class-6 patients only (P ≤ .05). However, there were no differences in total protein
between MMP-1 and TIMP-1. Active MMP-2 protein increased in class-4 and class-5 patients compared with active
MMP-1 and TIMP-1 (P ≤ .01). Western blotting did not identify the active component of MMP-9. Similarly, only the
latent form of MMP-9 was observed by gelatin zymography, whereas both the latent and active forms of MMP-2 were
observed. IHC demonstrated MMP-1 and MMP-2 in dermal fibroblasts and in perivascular leukocytes. TIMP-1 was
observed in basal-layer keratinocytes of the epidermis only. MMP-9 was not detected by IHC.
Conclusion: MMP synthesis is regulated at both the transcriptional and post-transcriptional levels in CVI. Our data sug-
gest that post-translational modifications are key to functional regulation. Dermal fibroblasts and migrating leukocytes
are probable cellular sources of MMPs. Increased active MMP-2 levels in class-4 and class-5 patients indicate tissue
remodeling caused by pre-ulcer and postulcer environmental stimuli. These data suggest that alterations in MMP-2
activity, in conjunction with TGF-β1–mediated events, cause an imbalance in tissue remodeling leading to a pro–ulcer-
forming environment. (J Vasc Surg 2001;34:930-8.)
MMPs, and increasing the synthesis of TIMPs.4,5 It is not
known whether this sequel of cytochemical reactions
applies to CVI. We have previously demonstrated that the
CVI-related cytochemical events involve excessive deposi-
tion of leukocyte-derived TGF-β1, increased matrix depo-
sition, and binding of TGF-β1 to dermal fibroblasts.7 We
hypothesized that the increased amounts of TGF-β1,
related to disease severity in our previous investigation,
would be associated with reduced messenger RNA
(mRNA) and protein levels of MMPs and increased levels
of mRNA and protein levels of TIMP-1. We focused our
study on MMP-1 (interstitial or fibroblasts collagenase),
MMP-2, and MMP-9 (gelatinases A and B) because they
degrade collagen and are transcriptionally regulated by
TGF-β1.6,8
METHODS
Patient selection and hemodynamic assessment
One hundred ten punch biopsies from the lower calf
or lower thigh were obtained from 73 patients. Biopsies
were separated into two groups and stratified according to
the International Society for Cardiovascular Surgery/
Society for Vascular Surgery clinical etiologic anatomic
distribution pathophysiology (CEAP) disease classification
for CVI9. Group 1 consisted of lower-calf biopsies that
were analyzed for MMP-1 and TIMP-1 gene expression
with quantitative reverse transcription and competitive
polymerase chain reaction (PCR)—normal skin (n = 16),
class 4 (n = 8), class 5 (n = 6), and class 6 (n = 9). Group
2 consisted of lower-calf and lower-thigh biopsies that were
analyzed for the active and latent protein components of
MMP-1, MMP-2, MMP-9, and TIMP-1—normal skin 
(n = 8), class 2 (n = 14), class 3 (n = 13), class 4 (n = 13),
class 5 (n = 11), and class 6 (n = 12). Gelatin zymography
for MMP-2 and MMP-9 was performed with a subset of
biopsies obtained from group 2—normal skin (n = 5), class
2 (n = 4), class 3 (n = 2), class 4 (n = 4), class 5 (n = 3),
and class 6 (n = 5).
To assure that the observed measurements were sec-
ondary to CVI alone, patients with any of the following
conditions were excluded: active infection, cancer, opera-
tion within 6 weeks, rheumatoid arthritis, use of steroid
medications, vasculitis, collagen vascular disease, and his-
tory or current use of intravenous drugs. Informed consent
was obtained before patients were enrolled into the study.
The research protocol was approved by the institutional
review boards of UMDNJ–New Jersey Medical School and
the East Orange Veterans Affairs Medical Center.
All CVI patients underwent venous duplex scans to
confirm the presence of venous reflux and the extent of
disease. The site of valvular incompetence, the pattern of
reflux, and the location of chronic venous obstruction in
deep and superficial systems were determined by using
duplex scanning as previously described by Araki et al.10
All duplex scan measurements were performed with a 5-
MHz imaging/5-MHz pulsed-wave Doppler color-flow
system (Quantum 2000, Siemens Inc, Seattle, Wash). The
majority of patients had bilateral lower-extremity venous
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 5 Saito et al 931
disease. Assignment to a clinical group was based on the
more severely affected limb.
Biopsy protocol
Biopsies were obtained as previously described.11 After
injecting the biopsy sites with 1% lidocaine, two 6.0-mm
punch biopsies were obtained from areas demonstrating
clinical signs of venous stasis dermatitis in the lower calf and
two were obtained from clinically healthy skin in the ipsilat-
eral lower thigh. Biopsy sites were closed with single 2-0
polypropylene sutures, and dressings were applied. Sutures
were removed on follow-up assessment of the wound 1
week later. In patients undergoing vein stripping and/or
perforator ligations, biopsies were obtained from incision
sites made during surgery. Biopsies from patients undergo-
ing surgery for infrainguinal revascularization served as nor-
mal controls. Control patients did not clinically exhibit
evidence of CVI. Two punch biopsies above the location of
their arterial insufficiency were obtained from the lower
thigh of each normal control patient. Lower-calf biopsies
were not obtained from this group because of the possibil-
ity of inducing wound complications.
Biopsies for MMP-1, MMP-2, MMP-9, and TIMP-1
gene expression and/or protein analysis were immediately
snap frozen in liquid nitrogen. Several biopsies were hemi-
sected and submerged in 2% paraformaldehyde/0.2% glu-
taraldehyde for 6 hours and then transferred to 70%
alcohol. These specimens were used for immunolocaliza-
tion of proteins.
Cytokine analysis
Total RNA isolation. Total RNA isolation and reverse
transcription were performed as previously described.7,11
Total cellular RNA was obtained from 50~100 mg of tissue
by the TRIzol method (GIBCO-BRL Life Technologies,
Gaithersburg, MD). Samples were homogenized, cen-
trifuged, and evaluated spectrophotometrically for quantity
and purity of total RNA.
Reverse transcription and competitive PCR. Reverse
transcription was performed by using the SuperScript
Preamplification System (GIBCO-BRL Life Technologies,
Gaithersburg, MD) to synthesize first-strand complemen-
tary DNA.7,11 After completion of first-strand cDNA syn-
thesis, samples were coamplified with the same volume of a
competitor cDNA fragment (internal standard) for each
PCR. The internal standards were created in the New Jersey
Medical School Molecular Resource Facility and standard-
ized as previously described.7 The sequences of the sense
and antisense primers for TIMP-1 and MMP-1 were the fol-
lowing: 5' ACC AGA AGT CAA CCA GAC CAC C and 3'
(558-540) TCC GTC CAC AAG CAA TGA G (corre-
sponding to nucleotides 191-211 and 558-540 of the
human TIMP-1 cDNA sequence) and 5' = AAG GTG ATG
AAG CAG CCC AG and 3' GAG CCG CAA CAC GAT
GTA AG (corresponding to nucleotides 321-340 and 720-
701 of the human MMP-1 cDNA sequence). PCR with
these primers amplified segments of the TIMP-1 and MMP-
1 gene that were 369 and 400 base pairs long, respectively.
Samples were amplified with a thermocycler (Gene Amp
PCR System 9600, Perkin-Elmer Corp, Norwalk, Conn).
Cycling was performed at 94°C for 45 seconds, annealing at
60°C for 45 seconds, and extension at 72°C for 120 sec-
onds. The number of PCR cycles was optimized for each tar-
get cDNA by cycle-response experiments.
Quantification of amplified products. Products
were quantified as previously described7. Each competitive
PCR product was analyzed with a 3% agarose gel elec-
trophoresis. Band intensity was quantified using the
Digital Imaging System (Alpha Innotech Corp, San
Leandro, Calif). To compensate for differences in band
intensity caused by fragment length, the ratio of mimic
length to target length was multiplied by the ratio of
mimic band to target band intensity to obtain a standard-
ized molecular ratio. The amount of target was calculated
by plotting the logarithm of the standardized molecular
ratios as a function of the known mimic amounts. A value
of zero for the logarithm of the standardized molecular
ratios (ordinate) corresponds to a molecular ratio of 1.
The abscissa value at this point is the amount of target.
Protein isolation. Frozen skin samples were thawed,
homogenized, and centrifuged. Total protein concentra-
tion was determined photometrically (Beckman DU 64
spectrophotometer, Salem, NH) using the Bradford assay
(Bio-Rad protein assay dye reagent, Bio-Rad, Hercules,
Calif) at 595 nm and known concentrations of bovine
serum albumin (Pierce Chemical Co, Rockford, Ill) as a
calibration standard. After quantification, samples were
analyzed by zymography and western blot for the degree
of protein activity and the amount of protein present per
sample, respectively.
Western blotting. Western blotting was performed as
previously described.12 Briefly, all four primary antibodies
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were mouse, antihuman, monoclonal immunoglobulin-G
(IgG) antibodies (1:100 for MMP-1, MMP-2, and TIMP-
1 and 1:200 for MMP-9) from different mouse strains, as
follows: MMP-1, Ab-1; MMP-2, Ab-3; MMP-9, Ab-8 and
Ab-3; and TIMP-1, Ab-2 (Oncogene Research Products,
Cambridge, Mass). Two MMP-9 primary antibodies were
used to increase the probability of detecting both the latent
and active forms of the enzyme. The secondary antibody
was a goat, antimouse, monoclonal IgG antibody (1:5000
dilution, Oncogene Research Products, Cambridge, Mass).
Positive controls were purified human proteins for MMP-
1 (Chemicon International Inc, Temecula, Calif) and
recombinant proteins for MMP-2, MMP-9, and TIMP-1
(Oncogene Research Products, Cambridge, Mass).
After transfer of electrophoresed proteins, all
polyvinyldiflouride membranes were incubated for 2 hours
in tris buffered saline with Tween 20 with 5% powdered
milk at room temperature. Bands were detected using
horseradish-linked immunoassay by enhanced chemilumi-
nescence western blotting detection reagents. Band inten-
sities were determined using the IS100 Digital Imaging
System (Alpha Innotech Corporation, San Francisco,
Calif). To standardize for differences in exposure times,
the ratios of sample band intensities to control were cal-
culated and used for statistical analysis.
Gelatin zymography. Proteolytic activity of MMP-2
and MMP-9 were assessed by gelatin zymography. To pre-
serve enzymatic activity, protein samples were not boiled and
the sample buffer did not contain mercaptoethanol. Samples
containing 100 µg of total protein were electrophoresed in a
10% polyacrylamide gel containing 0.1% sodium dodecyl sul-
fate and 2.0 mg/mL of gelatin at 4°C. Gels were subse-
quently stained with Coomassie Brilliant Blue R-250 staining
solution for 12 hours and destained with Coomassie Brilliant
Fig 1. Bar graph demonstrating results of quantitative reverse transcriptase PCR for MMP-1 and TIMP-1. mRNA levels for MMP-1
were increased in class-4 and class-6 patients (P ≤ .01). Gene transcripts for TIMP-1 were increased in class-6 patients only (P ≤ .05);
however, all TIMP-1 transcripts were increased five-fold compared with MMP-1.
Blue R-250 destaining solution (Bio-Rad, Hercules, Calif)
for 12 hours. A white band in the gel during densitometric
analysis demonstrated gelatinolytic activity.
Immunohistochemistry
Tissue preparations were probed with affinity purified
antibodies as previously described.7 The primary antibody
for MMP-2 was a monoclonal mouse, antihuman anti-
body (Strain Ab-6, Oncogene Research Products,
Cambridge, Mass); otherwise, the antibodies were the
same as for western blotting. The secondary antibody for
MMP-2 was a biotinylated goat, antimouse, monoclonal
IgG antibody (Vector Laboratories, Burlingame, Calif).
The blocking reagent used was goat serum (Vector
Laboratories, Burlingame, Calif). For each antibody, the
dilution that yielded optimal specific staining was deter-
mined in pilot experiments.
Specimens were immediately fixed in 2% parafor-
maldehyde/0.2% glutaraldehyde for 6 hours, transferred
to 70% alcohol, and paraffin-embedded the following day.
Once deparaffinized, sections were digested with 0.2%
hyaluronidase and incubated for 30 minutes at 37°C to
facilitate exposure of target epitopes. Incubation in 3%
hydrogen peroxide for 20 minutes exhausted endogenous
peroxidase activity. Immunohistochemistry protocols were
performed as previously described.7 Positive reactions
appeared dark brown on light microscopy. Negative con-
trols of healthy skin were treated with the secondary anti-
body alone, and the appropriate concentration that
demonstrated minimal background staining was used.
Statistical analysis. Differences between the means ±
standard error of the mean between groups were analyzed
with a one-way analysis of variance and the Newman-Keuls
post hoc tests. Differences in associated medical histories
between controls and patients with CVI were analyzed by
χ2 analysis. Significance was accepted at P ≤ .05.
RESULTS
Patient demographics. Fifty-four men and 19
women enrolled in the study. Mean ages of patients who
underwent gene transcript and protein evaluation were the
following: control, 59.9 years; class 2, 35.3 years; class 3,
41.1 years; class 4, 57.4 years; class 5, 58.4 years; and class
6, 53.9 years. Class-2 and class-3 patients were significantly
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younger than control patients and patients in classes 4
through 6 with CVI (P ≤ .01). Associated medical comor-
bidities are presented in Table I. No differences in medical
comorbidities were observed between control patients and
patients with CVI. One class-2 and one class-4 patient with
CVI had a previous vein stripping at presentation.
The clinical, etiologic, anatomic, and pathophysio-
logic distributions of CVI were determined clinically and
with duplex ultrasound scanning as per the recommended
reporting standards of the International Society for
Cardiovascular Surgery/Society for Vascular Surgery
(Table II). The distribution of reflux and the number of
patients with postphlebitic vein-wall changes detected by
duplex scan are summarized in Table III. Duplex data on
one class-4 and two class-6 patients were not available.
TIMP-1 and MMP-1 gene expression. The amounts
of MMP-1 mRNA in the groups were 0.002 ± 0.0005
(control), 4.15 ± 2.5 (class 4), 0.19 ± 0.15 (class 5), 31.2
± 13.9 (class 6), ×10–19 mol/µg total RNA, respectively.
Differences between class-4 and class-6 patients compared
with controls were significant (P ≤ .01 and P ≤ .001,
respectively) (Fig 1). The amounts of TIMP-1 in the four
groups were 2.56 ± 0.68 (control), 15.3 ± 6.51 (class 4),
5.66 ± 2.64 (class 5), 23.45 ± 11.29 (class 6), ×10–14
mol/µg total RNA respectively. Differences between class-
6 patients and controls were significant (P ≤ .05). TIMP-1
gene transcripts were five orders of magnitude greater than
those for MMP-1.
MMP-1, MMP-2, MMP-9, and TIMP-1 protein
expression. Analysis of total MMP proteins showed nei-
ther significant difference among groups nor significant
difference between diseased skin biopsies from the lower
calf and ipsilateral normal skin. Western blotting for
MMP-9 demonstrated the latent form of MMP-9 only.
Table I. Medical comorbidities
Control CVI
Comorbidity (n = 16) (n = 57) P value
Coronary artery disease 5 8 .32
Hypertension 5 13 1.0
Stroke 4 4 .21
Diabetes 3 4 .39
COPD 2 1 .19
Tobacco use 7 17 1.0
Deep venous thrombosis 0 5 .31
COPD, Chronic obstructive pulmonary disease.
Fig 2. Western blot demonstrating the latent band for MMP-9
from a lower-calf (LC) biopsy in a patient with an active venous
ulcer. The lower-calf and lower-thigh (LT) biopsies did not demon-
strate a band for the active component of MMP-9 (arrow indicates
90-kd band, corresponding to the latent form of MMP-9).
The active component of MMP-9 was not detectable by
western blotting in the protein extracts from CVI dermal
biopsies (Fig 2). To gain insight into the process of disease
progression, the relative amounts of MMP-1, MMP-2,
MMP-9, and TIMP-1 within each clinical group were
compared with each other. The active component of
MMP-2 was significantly elevated compared with those of
MMP-1 and TIMP-1 in class-4 and class-5 patients (Fig 3)
(P ≤ .01) in lower-calf biopsies only.
MMP-2 and MMP-9 activity. Both the active and
latent forms of MMP-2 were observed by zymography
(Fig 4). Consistent with the observations made with west-
ern blotting, only the latent form of MMP-9 was identi-
fied by gelatin zymography. However, the latent band for
MMP-9 was very large despite loading equal amounts of
protein in each lane. It is therefore possible that small
amounts of active MMP-9, corresponding to the 80-kd
band, may be imbedded in the wider latent MMP-9 band.
Immunohistochemistry. Immunoreactivity for MMP-
1, MMP-2, and TIMP-1 was observed on prepared tissue
specimens. MMP-1 and MMP-2 both localized to fibroblasts
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of the reticular and papillary dermis and cells traversing the
perivascular cuffs which appeared morphologically similar to
leukocytes (Figs 5, A-E). TIMP-1 was observed in ker-
atinocytes of the basal layer of the epidermis only (Fig 5, F ).
MMP-9 could not be localized with immunohisto-
chemistry. Because western blotting and zymography
detected the presence of latent MMP-9, it is plausible that
the amount of this MMP in skin is below the detection
threshold of immunohistochemistry.
DISCUSSION
We report experiments designed to investigate system-
atically the relationship among TGF-β1, MMPs, and
TIMP-1. In our previous investigations, we reported a
correlation between TGF-β1 and disease severity.7 Our
present study demonstrates a dissociation between mRNA
synthesis and protein production for specific MMPs in
patients with CVI. At the mRNA level, differences in
MMP-1 and TIMP-1 gene transcript levels, consistent
with transcriptional regulation by TGF-β1, were observed.
Overall, we measured low mRNA tissue levels of MMP-1
Table II. Clinical, etiologic, anatomic distribution, and pathophysiology data
Class 2 Class 3 Class 4 Class 5 Class 6
C2EpAs2,3,P18,PR C3EpAs2,3,D12,P18,PR C4EpAs2,3,D14,PR C5EpAs2,3,PR C6EpAs2-4,P18,PR
C2EpAs2,3,PR C3EpAs2,PR C4EpAs2,3,P18,PR C5EpAs2,3,D14,P18,PR C6EpAs2,3,PR
C2EpAs2,3,PR C3EpAs2,PR C4EpAs2,3,4,D11-14, C5EpAs2,3,PR C6EpAs2,3,D11-14,
P18,PR P18,PR
C2EpAs2,3,P18,PR C3EpAs2,3,P18,PR C4EpAs2,4,D13,14,PR C5EpAs4,5,D11,PR C6EpAs2,3,D14,PR
C2EpAs4,PR C3EpAs2,3,4,D14,PR C4EpAs2,3,PR C5EpAs2,3,P18,PR C6EpAs2,3,P18,PR
C2EpAs2,3,D11,P18,PR C3EpAs2,3,PR C4EpAs2,3,P18,PR C5EpAs4,P18,PR C6EpAs2,3,P18,PR
C2EpAs4,5,P18,PR C3EpAs2,3,5,PR C4EpAs3,4,PR C5EpAs2-4,D10-16, C6EpAs2,3,D13-15,
P18,PR P18,PR
C4EsAs4,5,D11-15, C5EpAs3,4,D13-15, C6EsAs2,3,D7-15,
PR,0 P18,PR P18,PRO
C4EpAs3,5,D11-14,PR C5EpAs2-4,D11-15, C6EsAs2,D6-13,PO
P18,PR
C4EpAs4,D11-15,PR C5EpAs2,3,D13,P18,PR C6EpAD13-15,P18,PR
C4EpAs2-4,D11-15,PR C5EpAs2,3,P18,PR C6EpAs2-4,P18,PR
CrEpAs2-4,PR C5EpAs2,3,D13,14, C6EpAs2,3,P18,PR
P18,PR
C4EpAs2,3,PR C6EpAs2-4,D9-15,
P18,PR
C4EpAs2,3,D4,PR C6EsAs2,D9-13,
P18,PRO
Table III. Distribution of reflux and postphlebitic disease
Reflux and postphlebitic disease Class 2 Class 3 Class 4 Class 5 Class 6 Total
S reflux 3 4 4 2 1 14
D reflux 0 0 0 0 0 0
P reflux 0 0 0 0 0 0
S and D reflux 0 1 7 1 2 11
S and P reflux 3 1 2 3 5 14
S, D, and P reflux 1 1 1 6 5 14
D and P reflux 0 0 0 0 1 1
Postphlebitic disease 0 0 0 2 3 5
S, Superficial; D, deep; P, perforator.
and increased levels of TIMP-1. However, their respective
protein levels did not differ significantly from controls.
These data suggest that although transcriptional regula-
tion of MMP-1 and TIMP-1 does occur, post-transla-
tional modifications, such as activation of preformed latent
precursors or leukocyte release of active forms, may be key
regulators of metalloproteinase synthesis and activity. This
interpretation is supported by our immunohistochemistry
data that identified perivascular leukocytes that stain posi-
tively for MMP-1 and MMP-2.
Our observations regarding MMP-2 and MMP-9 tis-
sue levels and activity are consistent with those of investi-
gators reporting an association between these
metalloproteinases and venous ulcer formation.13-15 These
authors reported that venous ulcer exudates demonstrated
increased active and latent forms of MMP-2 and MMP-9,
as compared with acute wound fluid, by gelatin zymogra-
phy. Other investigators have compared the expression
and activity levels of MMP-1, MMP-2, MMP-9, and
TIMP-1 of dermal biopsies of patients with lipoder-
matosclerosis to normal skin from healthy patients and
demonstrated increased MMP-1, MMP-2, and TIMP-1
gene and protein expression as well as increased MMP-2
activity.16 MMP-9 expression and activity were not
increased under similar conditions.6,16 To determine
whether these observations were specific to venous ulcer-
ation and lipodermatosclerosis or inherent to CVI, we
stratified patients according to the CEAP clinical classifi-
cation and studied patients with class-2 through class-6
disease. The active components of MMP-1, MMP-2, and
TIMP-1 were observed in all patients; however, significant
increases in MMP-2 activity were measured in class-4 and
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class-5 patients only. Similar to previous reports, we
detected active and latent forms of MMP-2 by zymogra-
phy.6,16 However, we identified only the latent form of
MMP-9 by western blotting and zymography. This differ-
ence may reflect activation of MMPs in ulcer exudates by
bacteria or other environmental factors compared with
protein extracts obtained directly from tissue biopsies.
Similarly, small amounts of active MMP-9 activity may
have been masked in our zymograms because of thickness
of the latent MMP-9 band.
The increased MMP-2 protein expression and its
gelatinolytic activity are consistent with the regulation of
MMP synthesis by TGF-β1 at the level of transcription.
TGF-β1 suppresses MMP gene expression by binding to an
inhibitory element of the MMP promoter, known as the
TGF-β-inhibitory element. Unlike other MMP promoters,
the MMP-2 promoter lacks an upstream TGF-β–inhibitory
element. Furthermore, TGF-β1 increases pro–MMP-2
gene expression and can induce activation by upregulating
matrix-bound MMPs.8 In our previous investigation, we
noted increased TGF-β1 levels from CVI dermal biopsies in
class-4, class-5, and class-6 patients and primary binding of
TGF-β1 to dermal fibroblasts.7 Therefore, it is reasonable
to conclude that increased MMP-2 levels and activity are a
consequence of alterations in TGF-β1 activity.
We found no significant differences between tissue lev-
els of MMP-2 in lower-calf biopsies compared with ipsi-
lateral normal skin. These data indicate that increased
tissue level and activity of MMP-2 are necessary but not
sufficient for venous stasis ulcer formation. Because of
these findings, we speculate that other factors such as
alterations in fibroblast contractile properties may con-
tribute to ulcer formation. This hypothesis is consistent
with clinical observations of tissue fibrosis and accelerated
ulcer formation after compromise of epidermal integrity in
patients with CVI.
Fig 4. Three-percent gel zymogram demonstrating gelatinolytic
activity of CVI skin protein extracts. The 92-kd band represents the
latent form of MMP-9. The 66-kd and 64-kd bands represent
active forms of MMP-2. MWkDa, Molecular weight in kilodaltons.Fig 3. Bar graph demonstrating tissue amounts of the active
components of MMP-1, MMP-2, and TIMP-1. The active com-
ponent of MMP-2 was increased in class-4 and class-5 patients
relative to MMP-1 and TIMP-1 (P ≤ .01). The active component
of MMP-9 was not observed.
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Fig 5. A, Dermal CVI biopsy of skin stained with hematoxylin alone (185×). Vertical arrow indicates basement membrane of epider-
mis. Horizontal arrow indicates dermal capillary. B, Dermal CVI skin biopsy. Dark brown granules indicate cells that are positive for
MMP-1. Vertical arrows point to spindle-shaped cells that appear similar to fibroblasts (185×). The horizontal arrow indicates a MMP-
1–positive leukocyte outside the perivascular cuff. C, Magnified view of right lower quadrant of Fig 5, B, demonstrating perivascular
cuffs. Arrows indicate circular cells traversing the cuffs which appear morphologically similar to leukocytes (460×). D, Dermal CVI skin
biopsy stained for MMP-2 and counterstained with hematoxylin. Blue dots are nuclei of dermal cells. Dark brown staining of the 
dermis is positive for MMP-2 (185×). E, Magnified view of right upper quadrant of Fig 5, D. Horizontal arrows indicate fibroblasts, and
vertical arrows indicate leukocytes traversing perivascular cuffs (460×). F, Dermal CVI skin biopsy. Vertical arrows indicate TIMP-1–
positive keratinocytes in the basal layer of the epidermis (185×).
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Based on our previous and current investigations, we
propose the following comprehensive theory on the etiol-
ogy of venous ulceration (Fig 6). Prolonged venous hyper-
tension results in dermal microcirculatory leakage of
macromolecules and extravasation of red blood cells. The
presence of these blood components in the dermal inter-
stitium initiates an inflammatory response resulting in
leukocyte recruitment. Interstitial leukocytes secrete TGF-
β1 that binds to dermal fibroblasts. Fibroblasts are subse-
quently stimulated to differentiate into myofibroblasts (a
known function of TGF-β1) and secrete MMP-2.
Additional MMP-2 may be contributed by interstitial
leukocytes. A combination of increased myofibroblast
contractility and concomitant MMP-2 activity results in
degradation of epidermal basement membrane collagen
type IV and subsequent loss of epidermal integrity (Fig 6).
Strategies aimed at modulating excessive metallopro-
teinase and TGF-β1 activity may therefore help to prevent
and heal venous ulcers.
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Fig 6. Diagram indicating the possible role of TGF-β1 and MMPs in venous ulcer formation.
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Dr Satoshi Saito. Thank you very much, Dr Menzoian.
Regarding your first question, we analyzed both the lower-calf
and lower-thigh biopsies, and there was no difference between
them. We obtained tissue samples from patients without chronic
venous insufficiency as control. This skin was clinically normal
and obtained from nonischemic areas of the thigh. Therefore, we
felt these biopsies were adequate normal controls.
Regarding the second question, we purposely did not biopsy
the ulcer edge. We consider ulcer-edge biopsies to be reflective of
a chronic wound environment and not representative of conditions
that predispose to ulcer formation. Therefore, in class-6 patients,
biopsies were taken several centimeters proximal to the ulcer edge.
Regarding the third question, we have consistently observed
that gene expression is not the major regulation point for growth
factor and metalloproteinase protein expression and activity. We
have therefore moved away from analysis of mRNA transcript lev-
els since protein activity seems to be dependent on post-tran-
scriptional in CVI.
Regarding the fourth question, our gene data for MMP-1
and TIMP-1 are consistent with the known effect of TGFb-1.
Similarly TGFb-1 stimulates MMP-2 synthesis. Although we have
no direct cause and effect experiments, our observations are con-
sistent with the reported activities of TGF-β1. We therefore
believe that these observations are interrelated.
Regarding the final question, we believe that MMP-2 levels
were not statistically significant in class-6 patients due to sample
size. If we had two or three more patients in the class-6 group,
MMP-2 probably would have been significant as well. We do not
think this is related to biopsy sites.
Thank you very much.
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